HENLIUS (02696): FDA Approves Phase 1 Clinical Trial Application for HLX13 as First-Line Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients

Stock News

Sep 29

HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has recently approved the Investigational New Drug (IND) application for a Phase 1 clinical trial of the company's self-developed ipilimumab biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The company plans to initiate this international multi-center clinical trial in the United States once conditions are met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191316700"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191316700\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191316700?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191316700","market":"sh","top_or_hot":-1,"title":"HENLIUS (02696): FDA Approves Phase 1 Clinical Trial Application for HLX13 as First-Line Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients","media":"Stock News","content":"<p>HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has recently approved the Investigational New Drug (IND) application for a Phase 1 clinical trial of the company's self-developed ipilimumab biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The company plans to initiate this international multi-center clinical trial in the United States once conditions are met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS (02696): FDA Approves Phase 1 Clinical Trial Application for HLX13 as First-Line Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS (02696): FDA Approves Phase 1 Clinical Trial Application for HLX13 as First-Line Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-29 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has recently approved the Investigational New Drug (IND) application for a Phase 1 clinical trial of the company's self-developed ipilimumab biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The company plans to initiate this international multi-center clinical trial in the United States once conditions are met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1191316700","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191316700","pubTimestamp":1759137132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has recently approved the Investigational New Drug (IND) application for a Phase 1 clinical trial of the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK4006":"钢铁","02696":"复宏汉霖","HCC":"Warrior Met Coal LLC"},"translate_title":"复宏汉霖(02696)：FDA批准HLX13一线治疗不可切除肝细胞癌(HCC)患者的1期临床试验申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1,"HCC":1},"content_text":"HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has recently approved the Investigational New Drug (IND) application for a Phase 1 clinical trial of the company's self-developed ipilimumab biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The company plans to initiate this international multi-center clinical trial in the United States once conditions are met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}